Literature DB >> 3277744

Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood.

P E Ball1, H Munzer, H P Keller, E Abisch, J Rosenthaler.   

Abstract

A specific radioimmunoassay involving a mouse monoclonal antibody to cyclosporine has been developed for monitoring the parent drug in blood. Pretreatment with methanol removes cyclosporine from the erythrocytes. The limit of detection is about 12 micrograms/L, sample volume is 50 microL of blood, and within- and between-assay CVs are less than 7%. Assay results correlated well with those obtained by "high-performance" liquid chromatography (HPLC) for liver (n = 42), for heart (n = 64), for bone-marrow (n = 36), and for kidney (n = 140). For blood specimens obtained from patients treated with cyclosporine postoperatively for as long as 65 months, the mean RIA/HPLC ratio in all with transplant indications was close to 1. Therefore, the specific radioimmunoassay apparently can be used instead of HPLC to measure the parent drug in blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277744

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; W Tetzloff; J Grevel; K Kutz
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

4.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

5.  Assessment of variables contributing to cyclosporine distribution in blood.

Authors:  S O Broin; E Clarke; S McCann
Journal:  Ir J Med Sci       Date:  1990 Sep-Dec       Impact factor: 1.568

6.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

7.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Cyclosporine A prevents neurological deterioration of patients with SAH--a preliminary report.

Authors:  M Ryba; M Pastuszko; K Iwanska; J Bidzinski; C Dziewiecki
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.

Authors:  M deLorgeril; P Boissonnat; C A Bizollon; J Guidollet; G Faucon; J P Guichard; R Levy-Prades-Sauron; S Renaud; G Dureau
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Effect of chronic administration of cyclosporin A on hepatic uptake and biliary secretion of bromosulfophthalein in rat.

Authors:  J F Cadranel; M Dumont; V A Mesa; C Degott; D Touchard; S Erlinger
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.